

ASX RELEASE

3<sup>rd</sup> July 2020

### Institutional Entitlement Offer Completed

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce it has successfully completed the Institutional Entitlement Offer component of the fully underwritten, accelerated, non-renounceable entitlement offer (**Entitlement Offer**). The Entitlement Offer was announced on 1<sup>st</sup> July 2020 and is raising a total of approximately \$4.0 million at \$0.10 per share.

The Institutional Entitlement Offer has raised \$2.0 million and was strongly supported by the Company’s largest shareholder, Platinum International Healthcare Fund, along with a new cornerstone shareholder who is highly experienced in biotechnology investments.

A total of 19.9 million new fully paid ordinary shares (**New Shares**) will be issued under the Institutional Entitlement Offer. The remaining 20.0 million New Shares will be offered under the Retail Entitlement Offer which will open on Wednesday 8<sup>th</sup> July 2020 and close on Tuesday 28<sup>th</sup> July 2020. Eligible Retail Shareholders will be entitled to apply for up to 3 New Shares for every 5 shares they hold on Friday 3<sup>rd</sup> July 2020 (**Record Date**) and are able to subscribe for New Shares over and above their Entitlement under a Shortfall Facility.

The New Shares subscribed for under the Institutional Entitlement Offer are expected to be issued on Friday, 10<sup>th</sup> July 2020.

The proceeds from the Entitlement Offer will be used to fund a Phase 1 clinical trial of the Company’s FAK inhibitor drug AMP945, additional non-clinical studies and provide additional working capital for the Company. Assuming a successful outcome, the data from the Phase 1 trial will be relevant for progressing AMP945 into Phase 2 trials in patients with certain advanced cancers or with fibrotic diseases, such as Idiopathic Pulmonary Fibrosis.

Commenting on the results of the Institutional Entitlement Offer, Amplia’s Chief Executive Officer Dr John Lambert said “We are very encouraged to see such strong support and commitment from existing and new institutional investors as we commence our transition to becoming a clinical stage drug development company”.

Taylor Collison is acting as Underwriter and Lead Manager to the Offer.

The Company’s ordinary shares will resume trading from market open today (Friday, 3<sup>rd</sup> July) on an ex-entitlement basis.

Please refer to the Company’s announcements lodged on ASX ([www.asx.com.au](http://www.asx.com.au)) for further information about the Entitlement Offer. Investors may also contact the Company on [info@ampliatx.com](mailto:info@ampliatx.com)

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

**For Further Information**

Dr. John Lambert  
Chief Executive Officer  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).